Cancer Drug Gets Priority FDA Review After Trial Shows No Signs of Tumors
FDA grants priority review to Jemperli after a trial shows yearlong disappearance of rectal tumors.
We haven't written up this one. Newsweek has the full story — the link below goes straight to it.